THE WOODLANDS, Texas,
April 27, 2015 /PRNewswire/
-- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a
biopharmaceutical company focused on developing breakthrough
treatments for human disease, will release its first quarter 2015
financial results on Wednesday, April 29,
2015 after the financial markets close. Lexicon
management will hold a conference call and webcast to discuss
clinical development progress and financial results for the first
quarter 2015 at 5:00 p.m. Eastern
Time on April 29, 2015.
The dial-in number for the conference call is 888-645-5785
(within the US/Canada) or
970-300-1531 (international). The conference ID for all
callers is 37172080. Investors can access a live webcast of
the call at www.lexpharma.com. An archived version of the
webcast will be available on the website through May 29, 2015.
About Lexicon
Lexicon is a biopharmaceutical company
focused on developing breakthrough treatments for human
disease. Lexicon has clinical-stage drug programs for
diabetes, carcinoid syndrome, and other indications, all of which
were discovered by Lexicon's research team. Lexicon has used
its proprietary gene knockout technology to identify more than 100
promising drug targets. For additional information about
Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains
"forward-looking statements," including statements relating to
Lexicon's growth and future operating results, discovery and
development of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management's current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including those relating to Lexicon's ability to meet its capital
requirements, successfully conduct preclinical and clinical
development of its drug candidates, obtain necessary regulatory
approvals, achieve its operational objectives, obtain patent
protection for its discoveries and establish strategic alliances,
as well as additional factors relating to manufacturing,
intellectual property rights, and the therapeutic or commercial
value of its drug candidates, that may cause Lexicon's actual
results to be materially different from any future results
expressed or implied by such forward-looking statements.
Information identifying such important factors is contained under
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2014, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lexicon-to-report-first-quarter-2015-financial-results-on-april-29-2015-300072766.html
SOURCE Lexicon Pharmaceuticals, Inc.